![](/wp-content/uploads/2022/01/Other-Research-Resources-440x300-1.png")
Latest News
Posts
;
Honored to serve in my new role as co-chair of @eaonc GU committee working with amazing @NaomiHaas5 & stellar colleagues nationwide! Have been in @eaonc for 11 years: huge progress, many opportunities ahead!
@MonikaJoshimd @fredhutch @HutchPresident @nicoleflemingmd
@OncoAlert
#ClinicalTrial EA5221/ACHIEVE, led by Dr. Megan Baumgart of @URMC_DeptMed & @WilmotCancer, aims to help older patients with #LungCancer live longer while also maintaining a good quality of life. Learn more: https://bit.ly/ea5221-achieve #NSCLC #LCSM
āThere has been ongoing controversy about whether ASCT still provides meaningful survival benefits in the modern treatment landscape.ā -Timothy S. Fenske, MD, MS on EA4151 clinical trial results - mantle cell lymphoma via @ascopost
Stem Cell Transplant May Not Be Necessary in First Remission for Patients With Mantle Cell Lymphoma...
Autologous stem cell transplantation (ASCT) does not improve survival outcomes for patients with mantle cell lymphoma ...
ascopost.com
About Us
The ECOG-ACRIN Cancer Research Group is a strong network of nearly 1300 academic and community-based cancer centers and hospitals in the United States and around the world. We design and conduct biomarker-driven research involving adults who have or are at risk of developing cancer. Learn More
Scientific Pursuits
We are dedicated to improving life for adults affected by cancer. Through our member sites, we are pursuing a robust clinical and translational research portfolio that focuses on precision oncology, immunotherapy, reducing over-treatment and over-diagnosis, leveraging novel biomarker platforms to inform therapeutic decision-making, and advancing standards of care in broad populations of cancer patients and those at risk. Learn More
ECOG-ACRIN by the Numbers
41
Active Clinical Trials
1400
Participating Institutions
67
International Sites
21000
Individual Members
Scientifically rigorous, broadly multidisciplinary, organizationally robust, and internationally respected, the Group is a vibrant component of the National Cancer Institute (NCI) National Clinical Trials Network (NCTN). In addition, we are a Research Base in the NCI Community Oncology Research Program (NCORP).
